1. Home
  2. ADPT vs PAGS Comparison

ADPT vs PAGS Comparison

Compare ADPT & PAGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • PAGS
  • Stock Information
  • Founded
  • ADPT 2009
  • PAGS 2006
  • Country
  • ADPT United States
  • PAGS Brazil
  • Employees
  • ADPT N/A
  • PAGS N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • PAGS EDP Services
  • Sector
  • ADPT Health Care
  • PAGS Technology
  • Exchange
  • ADPT Nasdaq
  • PAGS Nasdaq
  • Market Cap
  • ADPT 2.6B
  • PAGS 2.9B
  • IPO Year
  • ADPT 2019
  • PAGS N/A
  • Fundamental
  • Price
  • ADPT $20.36
  • PAGS $9.78
  • Analyst Decision
  • ADPT Strong Buy
  • PAGS Buy
  • Analyst Count
  • ADPT 10
  • PAGS 7
  • Target Price
  • ADPT $16.60
  • PAGS $11.71
  • AVG Volume (30 Days)
  • ADPT 2.4M
  • PAGS 5.0M
  • Earning Date
  • ADPT 11-05-2025
  • PAGS 11-12-2025
  • Dividend Yield
  • ADPT N/A
  • PAGS 1.43%
  • EPS Growth
  • ADPT N/A
  • PAGS 16.68
  • EPS
  • ADPT N/A
  • PAGS 1.37
  • Revenue
  • ADPT $252,754,000.00
  • PAGS $3,662,823,389.00
  • Revenue This Year
  • ADPT $36.43
  • PAGS $17.24
  • Revenue Next Year
  • ADPT $12.31
  • PAGS $6.77
  • P/E Ratio
  • ADPT N/A
  • PAGS $7.19
  • Revenue Growth
  • ADPT 42.57
  • PAGS 10.88
  • 52 Week Low
  • ADPT $4.76
  • PAGS $6.11
  • 52 Week High
  • ADPT $20.76
  • PAGS $11.16
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 73.37
  • PAGS 54.18
  • Support Level
  • ADPT $13.28
  • PAGS $9.15
  • Resistance Level
  • ADPT $14.24
  • PAGS $10.16
  • Average True Range (ATR)
  • ADPT 1.19
  • PAGS 0.48
  • MACD
  • ADPT 0.57
  • PAGS 0.03
  • Stochastic Oscillator
  • ADPT 95.19
  • PAGS 61.13

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About PAGS PagSeguro Digital Ltd.

PagSeguro Digital Ltd is a Brazilian-based company that acts as a provider of financial technology solutions focused on Micro-Merchants, Small Companies and Medium-Sized Companies (SMEs), in Brazil. The company provides a range of solutions and tools such as cash-in and cash-out options and provides access to working capital to help to manage its cash flow. It delivers an end-to-end digital ecosystem to address day-to-day financial needs, including receiving and spending funds and managing and growing businesses for clients. The company also offers the Free PagSeguro Digital Account delivering Cash-In Solutions, Online and In-Person Payment Tools, Online Payment Tools; and Web Check Outs offer tokenization, handling of shipping information, and others.

Share on Social Networks: